Pancreatic Cancer Research

ResearcherKyorin UniversityActive in the last 2 years

Junji Shibahara

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-8449-7039; OpenAlex author ID A5012150991. Sources: OpenAlex.

Their work

Papers
9 (first author 1, last author 3)
Trials
0
Grants
0
Labs led
1
Collaborators
18
Papers, trials and grants by year

2018: 2 papers · 2019: none · 2020: none · 2021: 1 paper · 2022: none · 2023: 1 paper · 2024: 1 paper · 2025: 1 paper · 2026: 3 papers

Papers 9

  1. Molecular landscape of anaplastic transformation in pancreatic ductal adenocarcinoma. Last author DOI 10.1002/path.70136↗
  2. Diagnostic utility of MUC4 expression for distinguishing pancreatic ductal adenocarcinoma from extrahepatic cholangiocarcinoma and its clinicopathological sign… Co-author DOI 10.1016/j.humpath.2026.106137↗
  3. Prognostic impact of imaging tumor regression adjacent to major arteries after preoperative chemotherapy in surgical patients with advanced pancreatic cancer. Last author DOI 10.1016/j.suronc.2026.102574↗
  4. Epigenetic evolution and clinicopathological implications of distinct DNA methylation profiles in pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/s41598-025-13919-y↗
  5. Combination immunohistochemistry for CK5/6, p63, GATA6, and HNF4a predicts clinical outcome in treatment-naïve pancreatic ductal adenocarcinoma. Last author DOI 10.1038/s41598-024-65900-w↗
  6. A Prospective Study of Neoadjuvant Gemcitabine Plus Nab-paclitaxel in Patients with Borderline-resectable Pancreatic Cancer. Co-author DOI 10.2169/internalmedicine.9504-22↗
  7. Effectiveness of introducing a 20-gauge core biopsy needle with a core trap in EUS-FNA/B for diagnosing pancreatic cancer. Co-author DOI 10.1186/s12876-020-01583-7↗
  8. Development of chemotherapy and significance of conversion surgery after chemotherapy in unresectable pancreatic cancer. First author DOI 10.1002/jhbp.547↗
  9. Long-term survival with repeat resection for lung oligometastasis from pancreatic ductal adenocarcinoma: a case report. Co-author DOI 10.1186/s40792-018-0435-2↗

Closest collaborators

The 18 strongest of 18 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Yoshihiro Sakamoto · 6 shared papers, 2023–2026 · strength 1.39
  2. Akimasa Hayashi · 5 shared papers, 2024–2026 · strength 1.23
  3. Takahiro Shibayama · 4 shared papers, 2024–2026 · strength 0.94
  4. Naohiro Okano · 3 shared papers, 2023–2026 · strength 0.62
  5. Ryota Matsuki · 3 shared papers, 2018–2026 · strength 0.54
  6. Keiichiro Kitahama · 2 shared papers, 2024–2025 · strength 0.42
  7. Christine A. Iacobuzio–Donahue · 2 shared papers, 2024–2026 · strength 0.40
  8. Junji Furuse · 3 shared papers, 2018–2023 · strength 0.38
  9. Masanori Sugiyama · 3 shared papers, 2018–2023 · strength 0.38
  10. Hirokazu Momose · 1 shared paper, 2026 · strength 0.29
  11. Saori Funakoshi · 1 shared paper, 2026 · strength 0.29
  12. Tadakazu Hisamatsu · 2 shared papers, 2021–2024 · strength 0.28
  13. Shunsuke Watanabe · 2 shared papers, 2021–2023 · strength 0.27
  14. Kaloyan M. Tsanov · 1 shared paper, 2026 · strength 0.23
  15. Scott W. Lowe · 1 shared paper, 2026 · strength 0.23
  16. Wungki Park · 1 shared paper, 2026 · strength 0.23
  17. Eileen Mary O'Reilly · 1 shared paper, 2026 · strength 0.23
  18. Fumio Nagashima · 1 shared paper, 2023 · strength 0.16

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.